Having established and characterized models of single-agent MET dependency in EGFR-mutant NSCLC, we next sought to understand why, despite expression of the mutant EGFR allele, these models were sensitive to single-agent MET inhibitors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.